Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma

被引:40
作者
Gao, Rebecca W. [4 ]
Berry, Mark F. [1 ]
Kunder, Christian A. [2 ]
Khuong, Amanda A. [1 ]
Wakelee, Heather [3 ]
Neal, Joel W. [3 ]
Backhus, Leah M. [1 ,5 ]
Shrager, Joseph B. [1 ,5 ]
机构
[1] Dept Cardiothorac Surg, Div Thorac Surg, Stanford, CA 94305 USA
[2] Dept Pathol, Stanford, CA 94305 USA
[3] Dept Med, Div Oncol, Stanford, CA 94305 USA
[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[5] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA
关键词
adenocarcinoma; lepidic; multifocal; adenocarcinoma in situ; non-small cell lung cancer; multiple pulmonary nodules; CELL LUNG-CANCER; FACTOR RECEPTOR MUTATION; GROUND-GLASS OPACITY; BRONCHIOLOALVEOLAR CARCINOMA; LIMITED RESECTION; CT FEATURES; LESIONS; CLASSIFICATION; PROGNOSIS; ASSOCIATION;
D O I
10.1016/j.jtcvs.2017.07.034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: It remains unclear whether a dominant lung adenocarcinoma that presents with multifocal ground glass opacities (GGOs) should be treated by local therapy. We sought to address survival in this setting and to identify risk factors for progression of unresected GGOs. Methods: Retrospective review of 70 patients who underwent resection of a pN0, lepidic adenocarcinoma, who harbored at least 1 additional GGO. Features associated with GGO progression were determined using logistic regression and survival was evaluated using the Kaplan-Meier method. Results: Subjects harbored 1 to 7 GGOs beyond their dominant tumor (DT). Mean follow-up was 4.1 +/- 2.8 years. At least 1 GGO progressed after DT resection in 21 patients (30%). In 11 patients (15.7%), this progression prompted resection (n = 5) or stereotactic radiotherapy (n = 6) at mean 2.8 +/- 2.3 years. Several measures of the overall tumor burden were associated with GGO progression (all P values < .03) and with progression prompting intervention (all P values < .01). In logistic regression, greater DT size (odds ratio, 1.07; 95% confidence interval, 1.01-1.14) and an initial GGO > 1 cm(odds ratio, 4.98; 95% confidence interval, 1.15-21.28) were the only factors independently associated with GGO progression. Survival was not negatively influenced by GGO progression (100% with vs 80.7% without; P = .1) or by progression-prompting intervention (P = .4). Conclusions: At 4.1-year mean follow-up, 15.7% of patients with unresected GGOs after resection of a pN0 DT underwent subsequent intervention for a progressing GGO. Some features correlated with GGO growth, but neither growth, nor need for an intervention, negatively influenced survival. Thus, even those at highest risk for GGO progression should not be denied resection of a DT.
引用
收藏
页码:2092 / +
页数:10
相关论文
共 31 条
[1]   A clinicopathological study of resected subcentimeter lung cancers: A favorable prognosis for ground glass opacity lesions [J].
Asamura, H ;
Suzuki, K ;
Watanabe, S ;
Matsuno, Y ;
Maeshima, A ;
Tsuchiya, R .
ANNALS OF THORACIC SURGERY, 2003, 76 (04) :1016-1022
[2]   Diameter of Solid Tumor Component Alone Should be Used to Establish T Stage in Lung Adenocarcinoma [J].
Burt, Bryan M. ;
Leung, Ann N. ;
Yanagawa, Masahiro ;
Chen, William ;
Groth, Shawn S. ;
Hoang, Chuong D. ;
Nair, Viswam S. ;
Shrager, Joseph B. .
ANNALS OF SURGICAL ONCOLOGY, 2015, 22 :S1318-S1323
[3]   Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21 [J].
Clark, Gary M. ;
Zborowski, Denni M. ;
Santabarbara, Pedro ;
Ding, Keyue ;
Whitehead, Marlo ;
Seymour, Lesley ;
Shepherd, Frances A. .
CLINICAL LUNG CANCER, 2006, 7 (06) :389-394
[4]   BRONCHOALVEOLAR CARCINOMA - FACTORS AFFECTING SURVIVAL [J].
DALY, RC ;
TRASTEK, VF ;
PAIROLERO, PC ;
MURTAUGH, PA ;
HUANG, MS ;
ALLEN, MS ;
COLBY, TV .
ANNALS OF THORACIC SURGERY, 1991, 51 (03) :368-377
[5]   A Dominant Adenocarcinoma With Multifocal Ground Glass Lesions Does Not Behave as Advanced Disease [J].
Gu, Bo ;
Burt, Bryan M. ;
Merritt, Robert E. ;
Stephanie, Stephanie ;
Nair, Viswam ;
Hoang, Chuong D. ;
Shrager, Joseph B. .
ANNALS OF THORACIC SURGERY, 2013, 96 (02) :411-418
[6]   CT Features of Epidermal Growth Factor Receptor-Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma [J].
Hasegawa, Mizue ;
Sakai, Fumikazu ;
Ishikawa, Rinako ;
Kimura, Fumiko ;
Ishida, Hironori ;
Kobayashi, Kunihiko .
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (06) :819-826
[7]   Surgical Management of Multifocal Ground-Glass Opacities of the Lung: Correlation of Clinicopathologic and Radiologic Findings [J].
Hattori, Aritoshi ;
Matsunaga, Takeshi ;
Takamochi, Kazuya ;
Oh, Shiaki ;
Suzuki, Kenji .
THORACIC AND CARDIOVASCULAR SURGEON, 2017, 65 (02) :142-149
[8]   TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer [J].
Herbst, RS ;
Prager, D ;
Hermann, R ;
Fehrenbacher, L ;
Johnson, BE ;
Sandler, A ;
Kris, MG ;
Tran, HT ;
Klein, P ;
Li, X ;
Ramies, D ;
Johnson, DH ;
Miller, VA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5892-5899
[9]   Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes [J].
Hong, Su Jin ;
Kim, Tae Jung ;
Choi, Yo Won ;
Park, Jeong-Soo ;
Chung, Jin-Haeng ;
Lee, Kyung Won .
EUROPEAN RADIOLOGY, 2016, 26 (10) :3660-3668
[10]   Management of Multiple Pure Ground-Glass Opacity Lesions in Patients with Bronchioloalveolar Carcinoma [J].
Kim, Hong Kwan ;
Choi, Yong Soo ;
Kim, Jhingook ;
Shim, Young Mog ;
Lee, Kyung Soo ;
Kim, Kwhanmien .
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (02) :206-210